

参 考 文 献

- [1] Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. *Ann N Y Acad Sci*, 1998, 850:251-259.
- [2] Vichinsky EP. Changing patterns of thalassemia worldwide. *Ann N Y Acad Sci*, 2005, 1054:18-24.
- [3] National Co-ordination Group of Haemoglobinopathy Research. A survey of haemoglobinopathy in 600,000 people of 20 provinces, cities and autonomous regions of China. *National Med J Chin*, 1983, 63:382-385.
- [4] 陈耀龙, 李幼平, 杜亮, 等. 医学研究中证据分级和推荐强度的演进. *中国循证医学杂志*, 2008, 8:127-133.
- [5] Forget BG, Cohen AR. Thalassemia syndromes// Hoffman R, Benz EJ, Shattil SS, et al. *Hematology: Basic Principles and Practice*. 4th ed. Philadelphia, Pa: Elsevier Churchill Livingstone, 2005, 35: 485-509.
- [6] Debaun MR, Vichinsky E. Hemoglobinopathies// Kliegman RM, Behrman RE, Jenson HB, et al. *Nelson Textbook of Pediatrics*. 18th ed. Philadelphia, Pa: Saunders Elsevier, 2007, 462:2025-2038.
- [7] Rund D, Rachmilewitz E. Beta-thalassemia. *N Engl J Med*, 2005, 353: 1135-1146.
- [8] Gu X, Zeng Y. A review of the molecular diagnosis of thalassemia. *Hematology*, 2002, 7: 203-209.
- [9] 张力, 区小冰, 余一平, 等. 广东地区 β 地中海贫血的基因分析与临床观察. *临床血液学杂志*, 2008, 21: 5-8.
- [10] 朱凌, 罗瑞贵, 周天红, 等. 广西地区 β 地中海贫血基因突变类型分析. *华南国防医学杂志*, 2009, 23:41-43.
- [11] Deng J, Peng WL, Li J, et al. Successful preimplantation genetic diagnosis for alpha- and beta-thalassemia in China. *Prenat Diagn*, 2006, 26:1021-1028.
- [12] Cazzola M, DeStrfano P, Ponchio L, et al. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. *Br J Haematol*, 1995, 89:473-478.
- [13] Cazzola M, Borgna-Pignatti C, Locatelli F, et al. A moderate transfusion regimen may reduce iron loading in beta-thalassaemia major without producing excessive expansion of erythropoiesis. *Transfusion*, 1997, 37:135-140.
- [14] Madgwick KV, Yardumian A. A home blood transfusion programme for beta-thalassaemia patients. *Transfus Med*, 1999, 9:135-138.
- [15] Rund D, Rachmilewitz E. Beta-thalassemia. *N Engl J Med*, 2005, 353:1135-1146.
- [16] Schrier SL, Angelucci E. New strategies in the treatment of the thalassemias. *Annu Rev Med*, 2005, 56:157-171.
- [17] Rebull P. Blood transfusion in beta thalassaemia major. *Transfus Med*, 1995, 5:247-258.
- [18] Davis BA, O'Sullivan C, Jarritt PH, et al. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. *Blood*, 2004, 104:263-269.
- [19] Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassaemia major. *N Engl J Med*, 2000, 343:327-331.
- [20] Deborah Chirmomas S, Geukes-Foppen M, Barry K, et al. Practical implications of liver and heart iron load assessment by T2*-MRI in children and adults with transfusion-dependent anemias. *Am J Hematol*, 2008, 83:781-783.
- [21] Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. *Br J Haematol*, 2003, 121:938-948.
- [22] Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. *Haematologica*, 2008, 93:741-752.
- [23] Yarali N, Fisgin T, Duru F, et al. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion. *J Pediatr Hematol Oncol*, 2006, 28:11-16.
- [24] Pippard MJ. Iron metabolism and iron chelation in the thalassaemia disorders. *Haematologica*, 1990, 75:66-71.
- [25] Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. *Semin Hematol*, 2005, 42:19-21.
- [26] Porter JB, Jaswon MS, Huehns ER, et al. Desferrioxamine toxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. *Br J Haematol*, 1989, 73: 403-409.
- [27] Maggio A, Vitranò A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. *Blood Cells Mol Dis*, 2009, 42: 247-251.
- [28] Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. *Blood*, 2006, 107:3738-3744.
- [29] Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. *Blood*, 2006, 107:3362-3455.
- [30] Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. *Blood*, 2008, 111:583-587.
- [31] Miyazawa K, Ohyashiki K, Urabe A, et al. A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. *Int J Hematol*, 2008, 88:73-81.
- [32] Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. *Br J Haematol*, 2003, 121:187-189.
- [33] Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. *Circulation*, 2007, 115:1876-1884.
- [34] Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. *N Engl J Med*, 1990, 322: 417-421.
- [35] 方建培. 造血干细胞移植治疗珠蛋白生成障碍性贫血的若干经验. *实用儿科临床杂志*, 2009, 24:164-167.
- [36] Ghavamzadeh A, Iravani M, Ashouri A, et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. *Biol Blood Marrow Transplant*, 2008, 14: 301-308.
- [37] Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalassemia. *Blood Rev*, 2008, 22: 53-63.
- [38] Modell B. Total management of thalassaemia major. *Arch Dis Child*, 1977, 52:489-500.
- [39] Cohen A, Markenson AL, Schwarz E. Transfusion requirements and splenectomy in thalassaemia major. *J Pediatr*, 1980, 97:100-102.
- [40] Pinca A, Di Palma A, Soriani S, et al. Effectiveness of partial splenic embolization as treatment for hypersplenism in thalassaemia major: a 7-year follow up. *Eur J Haematol*, 1992, 49:49-52.
- [41] Kalokairinou EM. The experience of beta-thalassaemia and its prevention in Cyprus. *Med Law*, 2008, 27:825-841.

(收稿日期:2010-01-09)

(本文编辑:关卫屏)